Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frespaciguat in PH-COPD
NCT04370873Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of frespaciguat in pulmonary hypertension (PH) (4 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants Who Experienced at Least 1 Adverse Event up to 139 days, Percentage of Participants Who Discontinued Study Drug Due to an AE up to 32 days and 1 more. Started Jun 2020; status: completed.
02
Drugs
frespaciguat
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT04370873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04370873.